Definium Therapeutics (DFTX) Total Assets by Year
Definium Therapeutics, Inc. closed fiscal year 2025 with $440.1M in total assets, $107.8M in total liabilities and $332.3M in shareholder equity. Total assets rose 45.7% from the prior fiscal year. The table below carries 6 fiscal years, from 2020 to 2025, and the quarters Definium Therapeutics, Inc. has filed alongside them.
Ticker history: MNMD became DFTX (Definium Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View MNMD history.
Annual figures, oldest first. Point at a bar to read its period.
DFTX Balance Sheet by Fiscal Year
Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|---|---|---|
| Total Assets | $440.1M+45.7% | $302.2M+142.6% | $124.5M-26.7% | $170.0M+3.7% | $164.0M+101.2% | $81.5M |
| Total Liabilities | $107.8M+77.5% | $60.7M+30.8% | $46.4M+143.3% | $19.1M+54.6% | $12.3M+118.3% | $5.7M |
| Total Equity | $332.3M+37.6% | $241.4M+209.0% | $78.1M-48.2% | $150.9M-0.5% | $151.7M+99.9% | $75.9M |
DFTX Balance Sheet by Quarter
Figures are in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.1B+353.4% | $1.1B+319.8% | $401.3M+45.8% | $440.1M+45.7% | $236.9M-25.9% | $265.1M-1.1% | $275.3M-0.1% | $302.2M+142.6% | $319.8M+125.9% | $268.1M+88.7% | $275.5M+77.2% | $124.5M-26.7% |
| Total Liabilities | $106.2M-0.1% | $194.2M+143.7% | $122.4M+133.2% | $107.8M+77.5% | $106.3M+84.7% | $79.7M+20.6% | $52.5M-33.9% | $60.7M+30.8% | $57.6M+26.3% | $66.1M+83.0% | $79.5M+215.6% | $46.4M+143.3% |
| Total Equity | $968.0M+641.2% | $918.7M+395.5% | $278.8M+25.2% | $332.3M+37.6% | $130.6M-50.2% | $185.4M-8.2% | $222.8M+13.6% | $241.4M+209.0% | $262.2M+173.2% | $202.0M+90.7% | $196.1M+50.4% | $78.1M-48.2% |
What total assets means
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders.
More Definium Therapeutics, Inc. financials
Frequently Asked Questions
Definium Therapeutics, Inc. closed fiscal year 2025 with $440.1M in total assets, $107.8M in total liabilities and $332.3M in shareholder equity.
Definium Therapeutics, Inc. (DFTX) total assets rose by 45.7% year over year, from $302.2M to $440.1M in fiscal year 2025.
Across the 6 fiscal years this page covers, Definium Therapeutics, Inc. (DFTX) total assets went from $81.5M in fiscal year 2020 to $440.1M in fiscal year 2025.
Definium Therapeutics, Inc. (DFTX) reported $1.1B in total assets in Q3 2026. This represents an increase of 353.4% from the same quarter a year earlier.
Total assets is everything the company owns on the balance sheet date, total liabilities is everything it owes, and the difference between them is the equity that belongs to shareholders. This page lists what Definium Therapeutics, Inc. (DFTX) reported on that line in every period on record.